We are cultivating a differentiated pipeline of small molecule medicines that utilize first-in-class or potential best-in-class mechanisms of action (MoAs) to restore balance in the brain by reducing the neuronal hyperexcitability that underlies debilitating brain conditions. Our unique understanding of the complexities of neurologic systems allows us to turn preclinical potential into clinical results.
Our aim is to make a meaningful impact and address the significant unmet need in the lives of individuals with neurological disorders that present with brain conditions.
Publications and Posters ยป
|
Programs |
Indication opportunities |
Preclinical |
Phase 1 |
Phase 2 |
|
+
|
OV329 |
|
GABA-aminotransferase inhibitor
|
Drug resistant adult focal onset seizures (FOS)
|
|
|
+
|
KCC2 direct activator portfolio |
|
OV350 IV
|
First-in-human direct activation of KCC2
|
|
|
OV4071 oral
|
Psychosis assoc. with Parkinson's disease and Lewy body dementia and schizophrenia
|
|
|
OV4041 oral
|
Generalized anxiety disorder and Rett syndrome
|
|
| Drug |
Indication |
Stage |
OV329
|
|
GABA-aminotransferase inhibitor
|
Drug resistant adult focal onset seizures (FOS)
|
Phase 1: Oral
|
KCC2 direct activator portfolio
|
|
OV350 IV
|
First-in-human direct activation of KCC2
|
Phase 1: IV-Completed
|
|
OV4071 oral
|
Psychosis assoc. with Parkinson's disease and Lewy body dementia and schizophrenia
|
Phase 1: Oral
|
|
OV4041 oral
|
Generalized anxiety disorder and Rett syndrome
|
Preclinical: Oral
|
*Ovid is focused on chronic oral formulations, including OV4071 and OV4041, and will not advance OV350 IV further in the clinic.